A
AnHeart Therapeutics
Precision medicine biopharmaceutical company leveraging expertise in clinical research and development and product registration focusing initially on oncology products
About AnHeart Therapeutics
AnHeart Therapeutics is a clinical-stage biopharmaceutical company that operates globally. The company is primarily focused on the development of innovative precision therapies for cancer patients. Their business model revolves around the research, development, and commercialization of novel drugs, with a recent focus on Taletrectinib, a ROS1 inhibitor. ROS1 inhibitors are a type of drug that blocks certain proteins that can contribute to cancer growth.
AnHeart Therapeutics operates in the biopharmaceutical market, a highly competitive and regulated industry. The company's clients are primarily healthcare providers and patients in need of cancer treatments. The company generates revenue through the successful development and subsequent sale of its drugs to healthcare providers.
Recently, AnHeart Therapeutics has been expanding its leadership in the U.S. and has also secured an exclusive license agreement with Nippon Kayaku for Taletrectinib in Japan. This suggests a strategic focus on both domestic and international growth. Furthermore, the company's new drug application for Taletrectinib has been accepted by China's NMPA, indicating progress in the drug's development and a potential new revenue stream upon successful market launch.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Mar 2024 | $0 | — | Nuvation Bio | ↗ |
| SERIES BOther financing | Dec 2021 | $61M | $244M | Innovent Biologics · Cenova Capital · Sage Partners · Octagon Capital Advisors | ↗ |
Growth signals
Latest recorded traffic for AnHeart Therapeutics is 1.4K monthly website visits, up 16.7% over the last three months. AnHeart Therapeutics's team declined 30.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AnHeart Therapeutics in the Huangpu ecosystem
The AnHeart Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Decheng Capital
Vertex Ventures China
Octagon Capital Advisors
Innovent Biologics
Cenova Capital
Sage Partners
Laurion Capital Management
Other known investors1 additional known investor
Nuvation Bio
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AnHeart Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AnHeart Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









